Last reviewed · How we verify
RepevaxTM
Repevax is a booster vaccine that provides protection against diphtheria, tetanus, pertussis, and poliomyelitis through immunization with inactivated antigens.
Repevax is a booster vaccine that provides protection against diphtheria, tetanus, pertussis, and poliomyelitis through immunization with inactivated antigens. Used for Booster vaccination against diphtheria, tetanus, pertussis, and poliomyelitis in adolescents and adults.
At a glance
| Generic name | RepevaxTM |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Inactivated combination vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Repevax contains inactivated toxoids of diphtheria and tetanus, acellular pertussis antigens, and inactivated poliovirus antigens. Upon administration, these antigens stimulate the immune system to produce antibodies and cellular immunity against these four pathogens, providing or reinforcing protection against these infectious diseases.
Approved indications
- Booster vaccination against diphtheria, tetanus, pertussis, and poliomyelitis in adolescents and adults
Common side effects
- Injection site pain
- Injection site swelling
- Injection site erythema
- Myalgia
- Headache
- Fatigue
Key clinical trials
- Immunogenicity and Safety of GSK Biologicals' Boostrix Polio Vaccine in 3 and 4-year-old Children (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |